



PRESS RELEASE

Woke Joins Medical Psychedelics Working Group of UK Drug Science

Highlights

- Joining leading independent scientific body on psychoactive drugs in the UK, Drug Science
- Access to UK-based Key Opinion Leaders in medical psychedelics
- Supports planned Phase II trial of high-dose psilocybin for major depressive disorder

03 November 2021 – Woke Pharmaceuticals Pty Ltd ('Woke' or 'the Company'), a Sydney NSW-based company focused on psychedelics for mental health, is pleased to announce that it has joined the Working Group for Medical Psychedelics of the UK-based Drug Science organisation, a leading independent scientific body on psychoactive drugs.

The Working Group's aim is to create a rational approach to psychedelic research and clinical treatment, ensuring the UK is a world leader in psychedelic medicine. The group explores innovation within the psychedelic space with a specific focus on how psychedelics can be integrated into primary and secondary healthcare. The Group supports evidence-based science and strong partnerships within the psychedelic community.

The Group is chaired by Professor Joanna Neill, Professor of Psychopharmacology at the University of Manchester. Other members include one of the eminent leaders in psychedelics and founder of Drug Science, Professor David Nutt, Professor of Neuropsychopharmacology and Director of the Neuropsychopharmacology Unit in the Division of Brain Sciences at Imperial College London.

The team at Drug Science is supporting Woke in the development of the Company's second clinical candidate, WP002, which is novel formulation of high-dose synthetic psilocybin, derived naturally from certain fungi, for the treatment of major depressive disorder. A Phase II trial is expected to commence in H2 CY2022 with concomitant psychotherapy.

Mr David Badcock, CEO of Drug Science, said: "We welcome Woke Pharmaceuticals to the Working Group for Medical Psychedelics, given their close relationship with us on development of their novel high-dose of psilocybin for treatment of major depressive disorder. The future of psychedelic medicine is extremely promising, and there is potential for widespread application of psychedelic drugs within public health models. The UK is a world leader in the development of clinical psychedelic research, which is now expanding globally."

Mr Nick Woolf, CEO of Woke Pharmaceuticals, commented: "We look forward to contributing to the important dialogue within Drug Science's Medical Psychedelics Working Group that aims to achieve a greater understanding amongst policy makers, academics, the media and the general public. There is strong evidence that medical psychedelics can be used safely, feasibly and with the potential for lasting therapeutic benefits. The Working Group includes key contributors to our planned clinical trial of WP002, high-dose psilocybin. We expect to announce details of the formulation work in the next few weeks."

ENDS

This announcement was authorised for release by the Directors of Woke Pharmaceuticals.

For more information, please contact:

Mr Nick Woolf
CEO
info@wokeph.com
+61 417 986 005



PRESS RELEASE

ABOUT WOKE PHARMACEUTICALS

Woke Pharmaceuticals Pty Ltd is an Australian-based company focused on the development and commercialisation of novel psychedelic therapies for the treatment of mental health disorders. The Company's lead candidates are based on synthetic psilocybin for the treatment of depression. Psilocybin is a naturally occurring psychedelic prodrug compound produced by more than 200 species of fungi. Clinical trials have shown its safety and efficacy in the treatment of depression and other disorders. Woke Pharmaceuticals is developing a novel micro-dose formulation for treatment of moderate depression and a novel high-dose formulation with concomitant psychotherapy for treatment of major depression. Both candidates are expected to enter Phase II trials in 2022 with leading investigators in the field of mental health. For further information, please visit www.wokeph.com.

Drug Science is a UK organisation that works to provide evidence-based R&D, and equipping the public, media and policy makers with the knowledge and resources to enact positive change. Drug Science remains a completely independent, science-led drugs charity, uniquely bringing together leading drugs experts from a wide range of specialisms, united with a passionate belief that the pursuit of knowledge should remain free of all political interest. Drug Science's mission is founded on their efforts, and their many hours of work delivering, reviewing, and investigating scientific evidence relating to psychoactive drugs, with one single minded message – to tell the truth about drugs.